Market Overview

UPDATE: Canaccord Genuity Initiates Coverage on Ducommun on Positive Catalysts Ahead

Share:

In a report published Thursday, Canaccord Genuity analyst Ken Herbert initiated coverage on Ducommun (NYSE: DCO) with a Buy rating and $34.00 price target.

In the report, Canaccord Genuity noted, “We are initiating coverage of Ducommun (DCO) with a BUY rating and a $34 price target. As execution continues to improve, confidence in cash flows and debt reduction should increase, serving as positive catalysts. We believe H2/13 represents the bottom for non-A&D sales, which should provide additional upside into 2014.”

Ducommun closed on Wednesday at $27.21.

Latest Ratings for DCO

DateFirmActionFromTo
Dec 2018SunTrust Robinson HumphreyInitiates Coverage OnBuy
Nov 2018Canaccord GenuityMaintainsBuyBuy
Aug 2018B. Riley FBRMaintainsBuyBuy

View More Analyst Ratings for DCO
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Ken HerbertAnalyst Color Initiation Analyst Ratings

 

Related Articles (DCO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
INTUMorgan StanleyMaintains245.0
TWLOKeyBancMaintains150.0
PLDKeyBancMaintains77.0
CSCOKeyBancMaintains58.0
BANDKeyBancMaintains75.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Jim Chanos Talks Long, Short And Ugly Trades

UPDATE: Canaccord Genuity Initiates Coverage on Esterline Technologies on Positive Catalysts, Continued Risks